Novartis shelves potential blockbuster pelacarsen after landmark study fails
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com - Novartis AG is largely abandoning the development of its experimental cardiovascular drug pelacarsen, once projected to be a multi-billion-dollar blockbuster, after full study data showed it failed to reduce heart attacks, strokes, or cardiovascular deaths…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bearishFailure of a drug once projected as a multi-billion blockbuster weighs on the growth outlook of a major drugmaker.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis is largely abandoning development of pelacarsen, an experimental cardiovascular drug.
- 02Full study data showed no reduction in heart attacks, strokes or cardiovascular deaths despite sharply lowering cholesterol.
- 03Novartis will keep only one mid-stage study active to evaluate the drug for calcific aortic valve stenosis.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Novartis AG162.55 USDMarket closedtoday +0.38%Negative Novartis AG160.97 USDMarket closedtoday +0.46%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets